Stock RGBP REGEN BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Company Regen BioPharma, Inc. Other OTC

Equities

RGBP

US75886M1027

Biotechnology & Medical Research

Business Summary

Regen BioPharma Inc. is a biotechnology company. The Company is engaged on the immunology and immunotherapy space. The Company is focused on novel technologies through pre-clinical and Phase I/ II clinical trials. It is involved on mRNA and small molecule therapies for treating cancer and autoimmune disorders. It is also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax, tCellVax, Dura-CAR, KimerApt), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate). HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients. tCellVax is a cell-based immunotherapy that stimulates the patient’s immune system through gene silencing of NR2F6.

Sales per Business

USD in Million2022Weight2023Weight Delta
Regenerative Medical Applications
100.0 %
0 100.0 % 0 100.0 % +0.44%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
0 100.0 % 0 100.0 % +0.44%

Managers

Managers TitleAgeSince
David Koos CEO
 Chief Executive Officer 64 24/12/24

Members of the board

Members of the board TitleAgeSince
David Koos CEO
 Chief Executive Officer 64 24/12/24

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 29,338 0 0 99.99 %
Stock B 0 34 0 0
Stock C 1 4,114,622 4,114,118 ( 99.99 %) 0
Stock D 0 409,551 0 0

Shareholders

NameEquities%Valuation
David Koos
0.0134 %
504 0.0134 % 378 $
Thompson Investment Management, Inc.
0.000107 %
4 0.000107 % 3 $
NameEquities%Valuation
David Koos
0.6680 %
334 0.6680 % 251 $
NameEquities%Valuation
David Koos
0.0243 %
7,667 0.0243 % 5 750 $
Harry Lander
0.0212 %
6,667 0.0212 % 5 000 $
Todd Caven
0.0212 %
6,667 0.0212 % 5 000 $
Jean-Pierre Millon
0.0127 %
4,001 0.0127 % 3 001 $
Robert D. Hopkins
0.006352 %
2,001 0.006352 % 1 501 $
Roger Formisano
0.006352 %
2,001 0.006352 % 1 501 $
NameEquities%Valuation
David Koos
100.00 %
15,007 100.00 % 11 255 $
NameEquities%Valuation
David Koos
29.84 %
122,221 29.84 % 318 997 $
RGBP Holdings LLC
9.999 %
40,949 9.999 % 106 877 $

Company contact information

Regen Biopharma, Inc.

4700 Spring Street Suite 304

91942, La Mesa

+619 722 5505

http://www.regenbiopharmainc.com
address Regen BioPharma, Inc.(RGBP)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+2.93% 106B
ARGENX SE Stock argenx SE
+7.02% 23.47B
BIONTECH SE Stock BioNTech SE
-14.60% 21.9B
GENMAB A/S Stock Genmab A/S
-7.05% 18.77B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.55% 17.85B
BEIGENE, LTD. Stock BeiGene, Ltd.
-8.83% 16.78B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.51% 14.41B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+37.49% 12.86B
VIKING THERAPEUTICS, INC. Stock Viking Therapeutics, Inc.
+329.39% 8.78B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. RGBP Stock
  4. RGBP Stock
  5. Company Regen BioPharma, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW